Stockreport

Assessing CorMedix (CRMD) Valuation After Recent Momentum Pause and Melinta Therapeutics Acquisition [Yahoo! Finance]

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF Investors are now weighing its year-to-date climb of 31% in comparison to its recent one month pause. See our latest analysis for CorMedix. CorMedix's momentum has s [Read more]